Advertisement

Recurrence and Complications After Laser Coagulation and Anti-VEGF Treatment

  • Ulrich Spandau
  • Sang Jin Kim
Chapter

Abstract

This chapter is about recurrence and complications after laser coagulation and anti-VEGF treatment. Recurrence and complications are very different in both treatment modalities and it is very important to know them.

Keywords

Laser coagulation Anti-VEGF treatment Recurrence Complications 

References

  1. 1.
    Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical management of recurrent retinopathy of prematurity after Intravitreal Bevacizumab monotherapy. Ophthalmology. 2016;123(9):1845–55.CrossRefGoogle Scholar
  2. 2.
    Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–15.CrossRefGoogle Scholar
  3. 3.
    Feng J, Qian J, Jiang Y, Zhao M, Liang J, Yin H, Chen Y, Yu W, Li X. Efficacy of primary Intravitreal Ranibizumab for retinopathy of prematurity in China. Ophthalmology. 2017;124(3):408–9.CrossRefGoogle Scholar
  4. 4.
    Hu J, Blair MP, Shapiro MJ, Lichetnstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after Bevacizumab injection. Arch Ophthalmol. 2012;130(8):1000–6.CrossRefGoogle Scholar
  5. 5.
    Early Treatment for Retinopathy of Prematurity Cooperative Group, Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Tung B, Redford M. Final visual acuity results in the early treatment for retinopathy of prematurity study. Arch Ophthalmol. 2010;128(6):663–71.CrossRefGoogle Scholar
  6. 6.
    Holmström G, Hellström A, Jakobsson P, Lundgren P, Tornqvist K, Wallin A. Five years of treatment for retinopathy of prematurity in Sweden: results from SWEDROP, a national quality register. Br J Ophthalmol. 2016;100(12):1656–61.CrossRefGoogle Scholar
  7. 7.
    Garcia Gonzalez JM, Snyder L, Blair M, Rohr A, Shapiro M, Greenwald M. Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity. Retina. 2018;38(4):764–72.CrossRefGoogle Scholar
  8. 8.
    Holmström G, Tornqvist K, Al-Hawasi A, Nilsson Å, Wallin A, Hellström A. Increased frequency of retinopathy of prematurity over the last decade and significant regional differences. Acta Ophthalmol. 2018;96(2):142–8.CrossRefGoogle Scholar
  9. 9.
    Repka MX, Tung B, Good WV, Shapiro M, Capone A Jr, Baker JD, Barr CC, Phelps DL. van. Thomas BJ, Yonekawa Y, Trese MT. Complete resolution of large retinal fold after transection of retrolental membrane during lens-sparing vitrectomy for retinopathy of prematurity: a 15-year follow-up. Retin Cases Brief Rep. 2016;10(1):93–5.CrossRefGoogle Scholar
  10. 10.
    Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855–9.CrossRefGoogle Scholar
  11. 11.
    Hu Q, Bai Y, Chen X, Huang L, Chen Y, Li X. Recurrence of retinopathy of prematurity in Zone II Stage 3+ after Ranibizumab treatment: a retropspective study. Ophthalmol. 2017;2017:5078565. Published online 2017 Apr 9.  https://doi.org/10.1155/2017/5078565.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Ulrich Spandau
    • 1
  • Sang Jin Kim
    • 2
  1. 1.OphthalmologyUniversity of Uppsala OphthalmologyUppsalaSweden
  2. 2.Department of OphthalmologySamsung Medical Center, Sungkyunkwan UniversitySeoulSouth Korea

Personalised recommendations